BCRX vs BFRI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BFRI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and BFRI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and BFRI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).

Full BCRX guide

Biofrontera Inc. is a US-based commercial-stage biopharmaceutical company that markets dermatology products, with its business centered on Ameluz, a topical photodynamic therapy (PDT) gel, used together with its RhodoLED family of red-light lamps. The primary approved use is treating actinic keratosis, common precancerous skin lesions caused by sun damage. The company sells to dermatology practices in the United States and reports high gross margins on the branded therapy, though it operates at a very small revenue base compared with large pharmaceutical peers.

Full BFRI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
• BFRI drivers: Ameluz franchise growth; Label-expansion catalysts.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard. For BFRI, biofrontera carries risks that are typical of a speculative micro-cap and then some.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCRX if you believe its drivers more; BFRI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and BFRI guides.

BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on GAAP earnings, since 2026 results were dominated by a roughly $698 million one-time non-cash acquired-IPR&D charge from the Astria deal that produced a large GAAP operating loss. On a non-GAAP basis the company reported operating profit and reaffirmed full-year revenue guidance. Because so much value sits in a single growing product plus a late-stage pipeline candidate, the market cap reflects expectations for peak ORLADEYO sales and navenibart success as much as trailing figures.

BFRI. These figures are approximate and qualitative, drawn from recent public reporting, and are not precise or real-time. Biofrontera is a very small, volatile company whose numbers can change quickly. Always verify current revenue, cash, share count, and regulatory status from primary sources before making any decision.

Headline figures (approximate, JUNE 2026): BCRX shows revenue (ttm) ~$630M, q1 2026 total revenue ~$156M, q1 2026 orladeyo revenue ~$148M (up ~11% YoY), 2026 orladeyo guidance ~$625M to $645M; BFRI shows revenue (ttm) Small but growing; full-year 2025 was roughly $40M with reported double-digit year-over-year growth continuing into 2026. Tiny versus large pharma peers., profitability Reported gross margins are high (near 80%), but the company has historically operated near or below net profitability at the bottom line., balance sheet Micro-cap with limited scale; may require additional financing over time, which can dilute existing holders. Verify current cash position live., valuation Trades as a speculative small-cap; conventional earnings-based multiples are of limited use when profitability is inconsistent. Sentiment is catalyst-driven..

BCRX and BFRI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCRX and BFRI exposure against your real portfolio. It is not an investment adviser.